Related Experiment Videos
[Nephrotoxicity of amphotericin B]
G Deray1, L Mercadal, C Bagnis
1Service de néphrologie, Groupe hospitalier Pitié-Salpêtrière, Paris. gilbert.deray@psl.ap-hop-paris.fr
Nephrologie
|June 29, 2002
Summary
Amphotericin B causes kidney damage in patients with severe fungal infections. Lipid formulations like Ambisome show reduced nephrotoxicity compared to conventional Amphotericin B, improving patient safety.
Area of Science:
- Mycology
- Nephrology
- Pharmacology
Context:
- Amphotericin B is a critical antifungal medication for life-threatening infections.
- Nephrotoxicity is a significant dose-dependent limitation of Amphotericin B therapy.
- Preventing renal dysfunction is essential due to links with hemodialysis and mortality.
Purpose:
- To evaluate the nephrotoxicity of Amphotericin B and its formulations.
- To compare the safety profiles of lipid-based Amphotericin B formulations.
- To identify strategies for minimizing Amphotericin B-induced renal complications.
Summary:
- Conventional Amphotericin B causes significant nephrotoxicity, including reduced glomerular filtration rate and tubular dysfunction.
- Newer lipid formulations, specifically Amphotericin B liposome (Ambisome), demonstrate reduced nephrotoxicity in clinical trials.
- Studies suggest Ambisome offers a better safety profile than Amphotericin B in lipid complex (ABLC, Abelcet), with less nephrotoxicity and fewer adverse events.
Impact:
- Highlights the clinical importance of managing Amphotericin B nephrotoxicity.
- Supports the use of lipid formulations like Ambisome for improved patient outcomes.
- Provides evidence for safer antifungal treatment strategies in severe infections.